Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is your one-stop shop for high-quality anti-CEA antibodies. Our extensive product line features antibodies with exceptional properties, including high specificity, sensitivity, and affinity for CEA. Whether you need antibodies for immunoprecipitation, Western blotting, ELISA, or other applications, we have the perfect solution for your research needs. Our dedicated customer support team is always available to assist you with product selection, technical inquiries, and order processing, ensuring a seamless and satisfying research experience.
Carcinoembryonic antigen (CEA) is a glycoprotein that serves as a non-specific marker in serum, closely linked to various endothelial cell activities such as adhesion, growth, and movement. Expressed on the luminal surface of normal cells, CEA is believed to inhibit apoptosis, potentially contributing to tumorigenesis. Elevated CEA levels have been observed in various cancers, including colorectal, medullary thyroid, breast, and mucinous ovarian, suggesting its potential as a therapeutic target for these malignancies.
Carcinoembryonic antigen; CEACAM1.
Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Consequently, CEA is usually present at very low levels in the blood of healthy adults (about 20 ng/mL). However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. Serum levels can also be elevated in heavy smokers.
Creative Biolabs specializes in offering high-quality anti-CEA antibodies designed for maximum precision and effectiveness in research. Our antibodies are meticulously crafted to ensure targeted performance, reducing cross-reactivity with other proteins. With a variety of customizable formats available, researchers can easily choose the antibody that best fits their unique experimental needs, enabling more extensive and impactful scientific exploration.
Table 1. Featured anti-CEA recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-0571-CN | Human Anti-CEA Recombinant Antibody | Human | Chimeric (mouse/human) IgG1, κ | ELISA, FC |
PABL-038 | Mouse Anti-CEA Recombinant Antibody (clone T84.66) | Human | Mouse IgG | ELISA, WB, FuncS |
HPAB-0569-CN | Mouse Anti-CEA Recombinant Antibody | Human | Mouse IgG | ELISA, FC |
FAMAB-0062YC | Mouse Anti-CEA Recombinant Antibody (clone Fl1-39) | Human | Mouse IgG | IP, FuncS |
PABL-037 | Mouse Anti-CEA Recombinant Antibody (clone MFE-23) | Human | Mouse IgG | ELISA, WB, FuncS |
Creative Biolabs is devoted to providing researchers with a wide choice of high-quality anti-CEA antibodies. Each antibody is thoroughly tested to ensure that it meets high quality requirements and performs optimally in a variety of applications. Our dedication to quality guarantees that our products meet the industry's most stringent standards, providing trustworthy and consistent results to help you advance your scientific study.
Fig.1 ELISA analysis of anti-CEA antibody
(Cat# HPAB-0569-CN, Creative Biolabs).
Creative Biolabs utilizes an advanced recombinant antibody platform that leverages state-of-the-art genetic engineering methods to generate high-quality anti-CEA antibodies. This pioneering approach enables streamlined and flexible production, ensuring a reliable availability of antibodies tailored to meet the diverse requirements of researchers in various demands.
Featured Anti-CEA Recombinant Antibody Production Platforms
Fig.2 Milligram-scale anti-CEA recombinant antibody production.
Fig.3 Gram-scale anti-CEA recombinant antibody production.
Creative Biolabs offers a wide selection of high-quality anti-CEA recombinant antibodies available in various formats tailored to suit your specific research needs.
Fig.4 Full-length anti-CEA recombinant antibody production and modalities.
Table 2. Public drug targeting CEA.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
Pre-Registered | Anti-CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; CD66e) | Monoclonal Antibodies | Hybritech (Originator) | |
Phase III | Drugs Targeting Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA; CD66e) |
Chimeric Monoclonal Antibodies Fluorescence Imaging Agents |
Cancer, colon Cancer, colorectal Cancer, colorectal, metastatic Cancer, metastatic (to brain) Cancer, metastatic (to lung) Cancer, pancreas Cancer, rectum Digestive-gastrointestinal cancer |
Institut Regional du Cancer Montpellier (Originator) Institut Regional du Cancer Montpellier SurgiMab (Originator) |
Phase III |
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers HER2 (erbB2)-Directed Immunity Inducers Melanoma-Associated Antigen 3 (MAGEA3; MAGE-3)-Directed Immunity Inducers Signal Transduction Modulators |
Cancer Immunotherapy Cancer Vaccines Peptides Peptide Vaccines |
Cancer, colorectal Cancer, lung Cancer, lung (non-small cell) (NSCLC) Cancer, ovary Cancer, pancreas Cancer, pancreas (ductal adenocarcinoma) |
Chong Kun Dang Bio Epimmune (Takeda) IDM (Takeda) OSE Immunotherapeutics Ose Pharma (OSE Immunotherapeutics) Rafa Laboratories Takeda (Originator) |
Phase II |
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers Mucin-1 (MUC1)-Directed Immunity Inducers |
Adenoviral Vectors Cancer Immunotherapy Cancer Vaccines Recombinant Vector Vaccines |
Lynch syndrome |
ImmunityBio (Originator) National Cancer Institute |
Phase II |
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers Mucin-16 (MUC16; CA125)-Directed Immunity Inducers |
Allogenic Cellular Vaccines Autologous Cellular Vaccines Cancer Immunotherapy Cancer Vaccines Polypeptides, from 41 AA Subunit Vaccines |
Cancer, breast |
Elliott-Elliott-Head Breast Cancer (Originator) OncImmune (Originator) |
Phase II | Anti-CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; CD66e) |
Bispecific Antibodies Cancer Immunotherapy Monoclonal Antibodies |
Cancer, thyroid, medullary |
Centre Hospitalier Universitaire Nantes Gilead (Originator) |
Phase II | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers |
Cancer Immunotherapy Cancer Vaccines DNA Vaccines |
Cancer of unspecified body location-system | Medical Marketing Int (d/b/a Oncosense) (Originator) |
Phase II | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers |
Cancer Immunotherapy Cancer Vaccines Recombinant Vector Vaccines |
Cancer, breast Cancer, breast, metastatic Cancer, colorectal Cancer, colorectal, metastatic Cancer, lung Cancer, metastatic (to liver) Cancer, pancreas Cancer, solid tumor |
National Cancer Institute Sanofi Pasteur Therion (Originator) |
Phase II | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers |
Cancer Immunotherapy Cancer Vaccines Recombinant Vector Vaccines |
Cancer, colorectal Cancer, colorectal, metastatic Immunological Disorders |
National Cancer Institute (Originator) Sanofi Pasteur Therion |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Creative Biolabs stands at the forefront of antibody research, combining a solid theoretical foundation with rich hands-on expertise to deliver cost-effective, premium-quality anti-CEA antibodies. For further information about our range of anti-CEA antibody products and to discover how they can enhance your research endeavors, feel free to reach out to us.